BioNeex, a NYC-based supplier of a biopharmaceutical business’s analysis and improvement (R&D) enterprise improvement platform, raised $500K in Seed funding.
The spherical was led by biopharma business leaders, together with former executives at Pfizer and Amgen.
The corporate intends to make use of the funds for product improvement, together with to reinforce the person expertise for BioNeex platform members.
Led by Dr. Smbat Rafayelyan, Founder and CEO, and Edgar Marukyan, Chief Know-how Officer, BioNeex gives a R&D enterprise improvement platform for the biopharmaceutical business, which is a market the place biotech and biopharma firms, together with enterprise capital companies come collectively to straight facilitate licensing and co-development partnerships for preclinical and clinical-stage drug candidates, and funding offers. BioNeex allows potential licensing and co-development companions and traders entry to the up-to-date data from drug candidate builders, and to contact them straight.
Commenting on the information, Smbat Rafayelyan mentioned: “Their funding in BioNeex will assist us proceed to supply new merchandise, providers and platform enhancements that enhance how drug improvement firms, potential companions and traders work together by way of the BioNeex market.“
FinSMEs
16/02/2024
